STELARA® Dosing Is Uniquely Designed for Crohn's Disease1
Single IV induction dose administered over at least 1 hour
|Body weight* of patient at the time of dosing||Dose||
Number of 130 mg/26 mL
(5 mg/mL) STELARA® vials
|55 kg or less||260 mg||2|
|more than 55 kg to 85 kg||390 mg||3|
|more than 85 kg||520 mg||4|
SubQ maintenance doses: 90 mg every 8 weeks
- STELARA® can be administered by a healthcare provider or by the patient after physician approval and proper training
- Please refer to the Dosage and Administration section of the Prescribing Information for complete information on how to prepare and administer STELARA®
*Approximately 2.2 pounds per kilogram.
Write 2 Prescriptions for STELARA® (ustekinumab)1
One for the single intravenous (IV) induction dose† and 1 for subcutaneous (subQ) maintenance treatment.
†The single IV infusion dose and number of vials are determined using a weight-based dosage regimen: STELARA® 260 mg (55 kg or less), STELARA® 390 mg (more than 55 kg to 85 kg), or STELARA® 520 mg (more than 85 kg). Please refer to the full Prescribing Information for the complete dosing information.
A Convenient Maintenance Dosing Schedule
7 doses of STELARA® in the first year1
Single IV induction dose administered over at least 1 hour‡
6 subQ injection maintenance doses (1 every 8 weeks)
STELARA® (ustekinumab) is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have:
- failed or were intolerant to treatment with immunomodulators or corticosteroids, but never failed treatment with a tumor necrosis factor (TNF) blocker, or
- failed or were intolerant to treatment with one or more TNF blockers.
27 doses of Humira® in the first year2§
6 starter injections in 2 doses
25 subQ injection maintenance doses (1 every other week)
Humira® (adalimumab) is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy. Humira® is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.2
This is not intended to compare the safety, effectiveness, or uses of these treatments. Please refer to each product’s Prescribing Information for recommended dosing and administration. Humira® is a registered trademark of AbbVie Inc.
‡Induction dose: A single IV infusion using a weight-based dosage regimen: STELARA® 260 mg (weight 55 kg or less), STELARA® 390 mg (weight more than 55 kg to 85 kg), STELARA® 520 mg (weight more than 85 kg). Maintenance dose: A subQ 90-mg dose administered every 8 weeks after the induction dose.1
§The recommended dosing for HUMIRA® in Crohn’s disease is 160 mg initially on Day 1 (given in one day or split over two consecutive days), followed by 80 mg 2 weeks later (Day 15). Two weeks later (Day 29) begin a maintenance dose of 40 mg every other week.2
References: 1. STELARA [package insert]. Horsham, PA: Janssen Biotech, Inc; 2016. 2. Humira® [prescribing information]. North Chicago, IL: AbbVie Inc; 2016.